Amazon’s healthcare venture with J.P. Morgan and Berkshire Hathaway has been named “Haven.” The name comes from the company’s goal to act as a partner to healthcare providers and the 1.2 million employees working for the three firms comprising the venture. Haven also unveiled its website, which shares more details and areas of focus. (CNBC)

Bristol-Myers Squibb sent a letter to investors asking for support for its $74 billion acquisition of Celgene, saying Celgene’s oncology pipeline will help the company grow. The shareholder vote is set for next month. Last week, two hedge funds voiced opposition to the deal. (CNBC)

The latest episode of The MM&M Podcast is here, featuring Cecelia Health’s David Weignard. The episode includes a discussion about how digital health is powering pharma’s latest patient-support paradigm, as well as Weingard’s panel on the future of value-based reimbursement at MM&M’s 2019 Transforming Healthcare conference. (MM&M)

A Canadian advisory council said a national drug agency should be created to manage and oversee prescription drug coverage. The agency would negotiate with manufacturers and monitor safety and effectiveness, along with other tasks. Prescription drugs in Canada are not universally covered. (Reuters)

The FDA approved a nasal spray depression treatment from Johnson & Johnson. Esketamine, a drug related to ketamine, is the first major depression treatment to be approved in the U.S. in decades. The nasal spray would be used in addition to oral antidepressants. Its wholesale acquisition cost is between $590 and $885 per session, with two sessions scheduled a week. (STAT)